Welcome to our dedicated page for Lantern Pharma SEC filings (Ticker: LTRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lantern Pharma Inc. (NASDAQ: LTRN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as an AI-driven, clinical-stage oncology and pharmaceutical preparation manufacturing issuer. Through documents filed with the U.S. Securities and Exchange Commission, investors can review how Lantern reports its financial condition, governance decisions, and material events related to its RADR® AI platform and oncology drug pipeline.
Lantern files annual reports on Form 10-K and quarterly reports on Form 10-Q that describe its business model, risk factors, clinical programs such as LP-184, LP-284, and LP-300, and the role of its RADR® artificial intelligence and machine learning platform in oncology drug discovery and development. Current reports on Form 8-K disclose specific material events, including quarterly financial results, at-the-market equity offering agreements, changes to bylaws, board appointments, and outcomes of annual stockholder meetings, such as director elections and equity incentive plan matters.
Proxy materials, including definitive proxy statements on Schedule 14A, outline Lantern’s corporate governance structure, proposals submitted to stockholders, and details on topics like the repricing of stock options under its equity incentive plan or the ratification of independent auditors. These filings help investors understand how Lantern’s board and management approach capital structure, executive compensation, and shareholder rights as the company advances its AI-enabled oncology strategy.
On Stock Titan, Lantern’s SEC filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify discussion of the RADR® platform, clinical trial progress, regulatory designations, and financing arrangements. Users can monitor real-time updates from EDGAR, review historical filings for context on LTRN’s evolution, and examine governance and compensation disclosures alongside clinical and platform milestones. This page is a central reference for anyone analyzing Lantern Pharma’s regulatory record, from long-form 10-K narratives to focused 8-K announcements.
Lantern Pharma Inc. filed a current report describing an investor and stakeholder event held on January 22, 2026. During this event, the company used a presentation to support discussions and a live demonstration of its initial artificial intelligence tools and multi-agent system that are being developed to focus on rare cancers. The same presentation is furnished as Exhibit 99.1 to the report and is not treated as formally filed financial information. This update is intended to share information under Regulation FD, giving the market equal access to the materials used at the event.
Lantern Pharma Inc. reported that director D. Jeffrey Keyser received two grants of stock options in the company. On January 9, 2026, he was awarded a stock option to buy 25,000 shares of common stock at an exercise price of $3.49 per share and a second stock option to buy 28,844 shares of common stock at the same $3.49 exercise price.
The first option for 25,000 shares will vest in equal monthly installments over 24 months starting February 9, 2026. The second option for 28,844 shares will vest in equal monthly installments over 12 months starting February 9, 2026. Both grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan, and the filing shows these option holdings as directly owned by the reporting person.
Lantern Pharma Inc. director Maria-Luisa Maccecchini reported receiving two stock option grants. On January 9, 2026, she was awarded a stock option to buy 25,000 shares of common stock at an exercise price of $3.49 per share, with the option priced at $0.00 on the grant date. She also received a second stock option for 21,152 shares at the same $3.49 exercise price.
Both grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The 25,000-share option vests in equal monthly installments over 24 months starting February 9, 2026, while the 21,152-share option vests in equal monthly installments over 12 months beginning on the same date. Following these grants, she directly beneficially owns 25,000 and 21,152 derivative securities, respectively.
Lantern Pharma Inc. director Chandru Vijay reported receiving two new stock option grants. On January 9, 2026, he was granted stock options to buy 25,000 shares of common stock at an exercise price of $3.49 per share under the company’s Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.
On the same date, he also received stock options to buy an additional 17,307 shares of common stock at an exercise price of $3.49 per share under the same plan. This second grant vests in equal monthly installments over 12 months beginning February 9, 2026. Both grants are reported as directly owned derivative securities.
Lantern Pharma director Lee Troy Schalop reported new equity awards on a Form 4. On January 9, 2026, he received two grants of stock options (rights to buy common stock) with an exercise price of $3.49 per share. One grant covers 25,000 options that vest in equal monthly installments over 24 months starting February 9, 2026. The second grant covers 18,460 options that vest in equal monthly installments over 12 months starting the same date. Both awards were reported at a transaction price of $0.00 per option, reflecting that these are option grants rather than open-market purchases or sales.
Lantern Pharma Inc. director David S. Silberstein reported receiving two grants of stock options to buy the company’s common stock. On January 9, 2026, he was awarded 25,000 stock options with an exercise price of $3.49 per share under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.
On the same date, he also received an additional 17,307 stock options with the same $3.49 exercise price under the same plan. This second grant vests in equal monthly installments over 12 months beginning on February 9, 2026. Both grants are held directly by Silberstein and represent compensation in the form of equity incentives rather than an open‑market purchase.
Lantern Pharma (LTRN) reported administrative updates via Form 8-K related to third-quarter communications. The company will release financial results for the quarter ended September 30, 2025 and host a conference call and live webinar on November 13, 2025. A press release is furnished as Exhibit 99.1 and an investor presentation as Exhibit 99.2. These materials are furnished, not filed, under the Exchange Act, so they are not subject to Section 18 liability or automatically incorporated into other filings.
Lantern Pharma (LTRN) filed its Q3 2025 10‑Q, reporting a net loss of
Cash and cash equivalents were
To bolster liquidity, Lantern entered an at‑the‑market program of up to
Lantern Pharma Inc. filed a Form 8-K reporting voting tallies for one or more matters. The record shows totals including 5,189,274 votes and several vote-category counts such as 2,212,199, 2,214,833, 2,213,670, 2,213,088, and smaller counts listed as Against 758,870, Against 43,732, and Abstain 29,603 and 26,426. The filing names Lantern Pharma Inc. as a Delaware corporation and is signed by David R. Margrave, Chief Financial Officer.
Lantern Pharma (LTRN) director Vijay Chandru amended two outstanding stock options on 09/19/2025, replacing earlier awards with new options priced at $5.04 per share. The original options were granted on 06/15/2020 (9,135 underlying shares, originally $15 exercise price, expiration 06/14/2030) and 11/04/2021 (3,200 underlying shares, originally $10.32 exercise price, expiration 11/03/2031). The amendments cancelled the old options and granted replacement options covering the same share amounts, leaving Mr. Chandru with options for a total of 12,335 underlying shares exercisable under the stated expirations.